PMCF plan
Post-market surveillance template
PMCF plan for MDR/IVDR PMS and PMCF
Use this editable PMCF plan to collect, analyse and report post-market data in a way that satisfies PMS Plan, PMCF and PSUR requirements under Regulation (EU) 2017/745.
- Best for: PMS plans, PMCF evaluation, PSUR preparation, vigilance reporting and trend analysis.
- Includes: editable sections for data collection, analysis methods, conclusions and action tracking.
- Format: editable template available through the standard WooCommerce download flow.
Lexqara supports medical device manufacturers in building proactive post-market surveillance systems that keep clinical evidence current. Explore the Resource Center or review our Post-Market Surveillance Services.
Description:
This Post-Market Clinical Follow-Up Plan sets a controlled way to define, run, and document PMCF activities that keep clinical evidence current across the device lifecycle.
-
Define controlled identifiers (PMCFP-ZZZZ rev.Y, approvals, revision history, dates).
-
Record manufacturer contacts including SRN and PRRC details.
-
Describe the device and scope (Basic UDI-DI, EMDN, class/rule, expected lifetime, intended purpose).
-
Plan PMCF activities with objectives, rationale, limitations, and timelines (Table 4).
-
Specify general methods: literature search and vigilance/recall screening with named databases.
-
Specify specific methods where needed: device registry, PMCF investigation, patient/user survey with protocol essentials.
-
Link PMCF to CER and risk management outputs (Tables 5–6) and include similar/equivalent device evaluation (Table 7).
-
Reference applicable guidance (MDCG 2020-7, MDCG 2020-8) and define the PMCF evaluation report date.
Your needs:
-
PMCF plan template
-
PMCF plan template for MDR compliance
-
Reduce rework, tighten clinical evidence updates, and improve NB review readiness.
Use this template when drafting or updating PMCF planning to ensure PMCF activities, timelines, and evidence links remain consistent with your clinical evaluation and risk management approach.
It clarifies what to collect and why. PMCF activities are planned methods to confirm safety/performance and detect emergent risks. Equivalent/similar device evaluation extends monitoring to comparable technologies to support state-of-the-art alignment.
-
Control document approval, revision, and traceable identifiers.
-
Define device scope and intended purpose inputs from IFU/TD/CER.
-
Plan literature and vigilance/recall screening with databases and limitations.
-
Define study-like methods (registry/investigation/surveys) with endpoints and approvals.
-
Capture CER and risk file gaps/risks to be followed up.
-
Set collection, analysis, and reporting timelines aligned to PMS planning.
At Lexqara, we develop PMCF plans and evaluation pathways that integrate clinical documentation, PMS signals, and risk management updates—built for audit and submission workflows. Resource Center [https://lexqara.com/resource-center] and Clinical Documentation support [https://lexqara.com/services/clinical-documentation]. MDCG 2020-7 guidance [https://health.ec.europa.eu/system/files/2020-06/mdcg_2020_7_guidance_on_pmc_plan_template_en_0.pdf]. Download the template or request a short gap assessment.
Template preview
Template preview: PMCF plan
Review the key sections included in the PMCF plan template before downloading it. This preview shows the structure and content you will receive in the editable file.
View the full template preview
Post-Market Clinical Follow-Up (PMCF) Plan
For
[Device Name]
Manufacturer Name: [Manufacturer name]
Document Number: XXXX
Revision: XXXX
Date: DD/MM/YYYY
Approval
Reviewer
|
Name: |
Date: |
|
Title: |
Signature: |
Approver
|
Name: |
Date: |
|
Title: |
Signature: |
|
Name: |
Date: |
|
Title: |
Signature: |
Revision history
Table 1: History of revisions
|
Revision |
Revision date |
Description of change |
Revised by |
|---|---|---|---|
Manufacturer contact details
The following table includes the manufacturer details.
Table 2: Contact information
|
Contact information |
Description |
|---|---|
|
Legal manufacturer name: |
|
|
Address: |
|
|
Single Registration Number (SRN): |
|
|
Person responsible for regulatory compliance (PRRC): |
|
|
E-mail: |
|
|
Phone: |
|
|
Fax: |
|
|
Authorized Representative: |
|
|
Address: |
|
|
Contact Person: |
|
|
E-mail: |
|
|
Phone: |
|
|
Fax: |
Medical Device description and specification
General medical device details.
The following table includes the general information on [Device name] (hereafter named [device short name]).
Table 3: Medical device details
|
Medical device information |
Description |
|---|---|
|
Product or trade name |
|
|
Model and type |
XXXX / See appendix I |
|
Basic UDI-DI |
|
|
EMDN code (CND code) |
XXXX / See appendix I |
|
Certificate number (if applicable) |
|
|
Class and classification rule |
Class X under Rule Y / Refer to appendix I |
|
Expected lifetime |
XXXX / See appendix I |
|
Novelty: |
|
|
Yes/No if yes describe the novelty |
|
Yes/No if yes describe the novelty |
General description of the device
Copy/paste from the TD (or CER)
List and description of any variants and/or configurations covered by this plan
Copy/paste from the TD (or CER)
List of any accessories covered by this plan
Copy/paste from the TD (or CER)
Intended purpose
Copy/paste from the IFU (or TD if no IFU)
Intended users
Copy/paste from the IFU (or TD if no IFU)
Intended patient population
Copy/paste from the IFU (or TD if no IFU)
Medical condition(s)
Copy/paste from the IFU (or TD)
Indications
Copy/paste from the IFU (or TD if no IFU)
Contraindications
Copy/paste from the IFU (or TD if no IFU)
Warnings
Copy/paste from the IFU (or TD if no IFU)
Activities related to PMCF: general and specific methods and procedures
The following table describes the planned general and specific methods and procedures of PMCF for [device short name]. All planned PMCF activities are further described in the next sections.
This PMCF plan covers the period from YYYY/MM/DD to YYYY/MM/DD
This period should be aligned with the PMS plan
Table 4: Description of PMCF activities for [device short name]
|
Item |
PMCF activity |
Objective |
Description |
Rationale to be appropriate and known limitations |
Timelines |
|---|---|---|---|---|---|
|
General procedures and methods of PMCF |
|||||
|
C1 |
Screening of scientific literature for the subject device |
Select the appropriate objective(s)
|
Procedure: refer to an existing QMS procedure (if applicable) Description: Collection of scientific literature on [device short name] through implementation of literature search methodology via the following databases:
|
Rationale: Include a summary of the rationale for appropriateness Known limitations: e.g., incomplete follow up, missing data |
Collection: YYYY / QX-YYYY / MM-YYYY Analysis: YYYY / QX-YYYY / MM-YYYY Report: YYYY / QX-YYYY / MM-YYYY |
|
C2 |
Screening of vigilance and recalls in publicly available database for the subject device |
Select the appropriate objective(s)
|
Procedure: refer to an existing QMS procedure (if applicable) Description: Collection of vigilance/recall reported for [device short name] in the following publicly available databases:
|
Rationale: Include a summary of the rationale for appropriateness Known limitations: e.g., incomplete follow up, missing data |
Collection: YYYY / QX-YYYY / MM-YYYY Analysis: YYYY / QX-YYYY / MM-YYYY Report: YYYY / QX-YYYY / MM-YYYY |
|
Specific procedures and methods of PMCF |
|||||
|
C3 |
Device registry |
Select the appropriate objective(s)
|
Procedure: refer to an existing QMS procedure (if applicable) Description: consultation of device registry XXXX indicate the name of the registry to collect clinical evidence that supports the safety and performance of [device short name] |
Rationale: Include a summary of the rationale for appropriateness Known limitations: e.g., incomplete follow up, missing data |
Collection: YYYY / QX-YYYY / MM-YYYY Analysis: YYYY / QX-YYYY / MM-YYYY Report: YYYY / QX-YYYY / MM-YYYY |
|
C4 |
PMCF investigation |
Select the appropriate objective(s)
|
Procedure: refer to an existing QMS procedure (if applicable) Description: implementation of PMCF investigation to collect clinical evidence that supports the safety and performance of [device short name] |
Rationale: Include a summary of the rationale for appropriateness Known limitations: e.g., incomplete follow up, missing data |
Collection: YYYY / QX-YYYY / MM-YYYY Analysis: YYYY / QX-YYYY / MM-YYYY Report: YYYY / QX-YYYY / MM-YYYY |
|
C5 |
PMCF patient/user survey |
Select the appropriate objective(s)
|
Procedure: refer to an existing QMS procedure (if applicable) Description: The PMCF study under the form of collection of patient/user survey is intended to collect clinical data for specific safety and/or performance questions on [device short name] |
Rationale: Include a summary of the rationale for appropriateness Known limitations: e.g., incomplete follow up, missing data |
Collection: YYYY / QX-YYYY / MM-YYYY Analysis: YYYY / QX-YYYY / MM-YYYY Report: YYYY / QX-YYYY / MM-YYYY |
|
C6 |
Select the appropriate activity
… |
Select the appropriate objective(s)
|
Procedure: refer to an existing QMS procedure (if applicable) Description: include a summary of the method/procedure that will be further described in the next sections |
Rationale: Include a summary of the rationale for appropriateness Known limitations: e.g., incomplete follow up, missing data |
Collection: YYYY / QX-YYYY / MM-YYYY Analysis: YYYY / QX-YYYY / MM-YYYY Report: YYYY / QX-YYYY / MM-YYYY |
Screening of scientific literature for the subject device
Type of procedures and methods
General procedure and method.
Objective
Copy/paste the information from the summary table
Description
A literature search will be implemented to detect the published and unpublished articles related to the [device short name] and bring clinical evidence for the demonstration of safety and performance.
The literature search methodology will be carried out in compliance with Section A5 of MEDDEV 2.7/1 rev.4. Research questions will be constructed using a PICO (Populations, Interventions, Comparators, Outcomes) process to justify the selection of relevant keywords.
The literature search will be applied in the following databases:
- Embase
- PubMed
- Cochrane Library
- Google Scholar
- EU Clinical Trials Register
- Clinicaltrials.gov
- XXXX
In the literature databases, the search queries will be defined using the selected keywords in a way to match with the language of each database used. The queries will have to incorporate the relevant search limitations (e.g., article type, language, as applicable).
The result of literature search will be a list of articles that will be screened in two stages:
- Level-1 screening is based on the titles and abstracts
- Level-2 screening is based on the full articles
The screening process consists of the review of each collected article to confirm if it should be included or excluded based on the inclusion/exclusion criteria.
The literature search will be implemented according to a literature search protocol that is defined based on the literature search protocol from the last clinical evaluation report (CER). The results will be documented in a literature search report.
The post-market clinical follow-up (PMCF) evaluation report for [device short name] will analyze and summarize the findings resulting from the literature search report.
Rationale for appropriateness of the procedure/method
A rationale that supports how the method is appropriate, needs to be described.
Limitations
Further describe the limitations if applicable, as compared to the summary table above.
Screening of vigilance and recalls in publicly available database for the subject device
Type of procedures and methods
General procedure and method.
Objective
Copy/paste the information from the summary table
Description
A vigilance / recall search will be implemented to detect the clinical risks (i.e., device problem, patient problems) related to [device short name] and bring additional clinical evidence for the demonstration of safety and performance.
The vigilance / recall search methodology will be carried out using an approach similar to the literature search methodology. Research questions will be constructed using a PICO process to justify the selection of relevant keyword.
The vigilance / recall search will be applied in the following databases:
- FDA MAUDE
- FDA Medical Device Recalls
- ANSM safety information
- Bfarm Field Corrective Actions
- MHRA Alerts, recalls and safety information: drugs and medical devices
- SwissMedic – FSCA and recall
- DAEN (Database of Adverse Event Notifications) – medical devices
- SARA (System for Australian Recall Actions)
- Canadian recalls and safety alerts
- XXXX
In the vigilance / recall databases, the search queries will be defined using the selected keywords in a way to match with the language of each database used. The queries will have to incorporate the relevant search limitations (e.g., search period).
The result of vigilance / recall searches will be a list of events that will be screened to determine if applicable to [device short name].
The vigilance / recall search will be implemented according to a vigilance / recall search protocol that is defined based on the vigilance / recall search protocol from the last CER. The results will be documented in a vigilance / recall search report.
The post-market clinical follow-up (PMCF) evaluation report for [device short name] will analyze and summarize the findings resulting from the vigilance / recall search report.
Rationale for appropriateness of the procedure/method
A rationale that supports how the method is appropriate, needs to be described.
Limitations
Further describe the limitations if applicable, as compared to the summary table above.
Device registry
Type of procedures and methods
Specific procedure and method
Objective
Copy/paste the information from the summary table
Description
Clinical data from the registry XXXX Registry name relevant to [device short name] /or medical conditions treated by [device short name], will be collected according to the registry consultation protocol under XXXX rev.Y Document Number. Intermediary results will be documented in intermediary registry reports and final results will be documented in a final registry report.
The information relevant to the registry consultation is summarized in the following table with the estimated schedule.
|
Device registry requirements |
Device registry details |
||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Study design |
Registry |
||||||||||||||||||
|
Study objective |
|||||||||||||||||||
|
Geographic area |
|||||||||||||||||||
|
Population |
|||||||||||||||||||
|
Number of patients enrolled |
|||||||||||||||||||
|
Inclusion/exclusion criteria |
|||||||||||||||||||
|
Control group and justification |
|||||||||||||||||||
|
Study method |
|||||||||||||||||||
|
Follow-up duration |
|||||||||||||||||||
|
Endpoints |
|||||||||||||||||||
|
Need of notification/approval: |
Ethic committee (justification if not): |
||||||||||||||||||
|
NB (justification if not): |
|||||||||||||||||||
|
CA (justification if not): |
|||||||||||||||||||
|
Estimated schedule |
|
Rationale for appropriateness of the procedure/method
Per MDCG 2020-7, the following should be considered for specific procedures/methods:
- the justification for sample size, timescales and endpoints
- justification for comparator, on the basis of intended purpose and state of the art
- justification of the study design on the basis of all of the above, and why it is sufficient to ensure representative patient populations and provide for adequate controls on sources of bias (an evaluation of the potential sources of bias should form part of this)
- a statistical justification for the expected quality of outcomes, and justification for why this is satisfactory in light of the residual risks.
Limitations
Further describe the limitations if applicable, as compared to the summary table above.
PMCF investigation
Type of procedures and methods
Specific procedure and method
Objective
Copy/paste the information from the summary table
Description
The PMCF investigation has been defined based on the PMCF investigation protocol under XXXX rev.Y Document Number. Intermediary results will be documented in intermediary PMCF investigation reports and final results will be documented in a final PMCF investigation report.
The information relevant to the PMCF investigation is summarized in the following table with the estimated schedule.
|
PMCF investigation requirements |
PMCF investigation details |
||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Study design |
|||||||||||||||||||
|
Study objective |
|||||||||||||||||||
|
Geographic area |
|||||||||||||||||||
|
Population |
|||||||||||||||||||
|
Number of patients enrolled |
|||||||||||||||||||
|
Inclusion/exclusion criteria |
|||||||||||||||||||
|
Control group and justification |
|||||||||||||||||||
|
Investigator(s) |
|||||||||||||||||||
|
Investigation site(s) |
|||||||||||||||||||
|
Study method |
|||||||||||||||||||
|
Follow-up duration |
|||||||||||||||||||
|
Endpoints |
|||||||||||||||||||
|
Need of notification/approval: |
Ethic committee (justification if not): |
||||||||||||||||||
|
NB (justification if not): |
|||||||||||||||||||
|
CA (justification if not): |
|||||||||||||||||||
|
Estimated schedule |
|
Rationale for appropriateness of the procedure/method
Per MDCG 2020-7, the following should be considered for specific procedures/methods:
- the justification for sample size, timescales and endpoints
- justification for comparator, on the basis of intended purpose and state of the art
- justification of the study design on the basis of all of the above, and why it is sufficient to ensure representative patient populations and provide for adequate controls on sources of bias (an evaluation of the potential sources of bias should form part of this)
- a statistical justification for the expected quality of outcomes, and justification for why this is satisfactory in light of the residual risks.
Limitations
Further describe the limitations if applicable, as compared to the summary table above.
PMCF patient/user survey
Type of procedures and methods
Specific procedure and method
Objective
Copy/paste the information from the summary table
Description
The PMCF study is intended to collect clinical data for the patient/user perception for XXXX describe the specific concern identified.
The PMCF study has been defined based on the PMCF study protocol under XXXX rev.Y Document Number. Intermediary results will be documented in intermediary PMCF study reports and final results will be documented in a final PMCF study report.
The information relevant to the PMCF study is summarized in the following table with the estimated schedule.
|
PMCF study requirements |
PMCF study details |
||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Study design |
Patient/User survey |
||||||||||||||||||
|
Study objective |
|||||||||||||||||||
|
Geographic area |
|||||||||||||||||||
|
Population |
|||||||||||||||||||
|
Number of patients/users enrolled |
|||||||||||||||||||
|
Inclusion/exclusion criteria |
|||||||||||||||||||
|
Control group and justification |
|||||||||||||||||||
|
Investigator(s) |
|||||||||||||||||||
|
Investigation site(s) |
|||||||||||||||||||
|
Study method |
|||||||||||||||||||
|
Follow-up duration |
|||||||||||||||||||
|
Endpoints |
|||||||||||||||||||
|
Need of notification/approval: |
Ethic committee (justification if not): |
||||||||||||||||||
|
NB (justification if not): |
|||||||||||||||||||
|
CA (justification if not): |
|||||||||||||||||||
|
Estimated schedule |
|
Rationale for appropriateness of the procedure/method
Per MDCG 2020-7, the following should be considered for specific procedures/methods:
- the justification for sample size, timescales and endpoints
- justification for comparator, on the basis of intended purpose and state of the art
- justification of the study design on the basis of all of the above, and why it is sufficient to ensure representative patient populations and provide for adequate controls on sources of bias (an evaluation of the potential sources of bias should form part of this)
- a statistical justification for the expected quality of outcomes, and justification for why this is satisfactory in light of the residual risks.
Limitations
Further describe the limitations if applicable, as compared to the summary table above.
PMCF Activity C6 copy/paste the general procedure indicated in the summary table
Type of procedures and methods
Specific procedure and method
Objective
Copy/paste the information from the summary table
Description
Further describe the PMCF activity
Rationale for appropriateness of the procedure/method
Per MDCG 2020-7, the following should be considered for specific procedures/methods:
- the justification for sample size, timescales and endpoints
- justification for comparator, on the basis of intended purpose and state of the art
- justification of the study design on the basis of all of the above, and why it is sufficient to ensure representative patient populations and provide for adequate controls on sources of bias (an evaluation of the potential sources of bias should form part of this)
- a statistical justification for the expected quality of outcomes, and justification for why this is satisfactory in light of the residual risks.
Limitations
Further describe the limitations if applicable, as compared to the summary table above.
Reference to the relevant parts of the technical documentation
Relevant information from the clinical evaluation report
This PMCF plan for [device short name] is defined based on the outputs of the clinical evaluation report (CER) XXXX rev.Y approved on DD Month YYYY.
The relevant information from the CER to be specifically analyzed, followed-up, and evaluated are gathered in the following table.
Table 5: Relevant information from the CER
|
Relevant information from the CER |
CER section(s) |
|---|---|
|
Indicate the weaknesses/gaps with the clinical evaluation (e.g., the CER is based on the equivalence and the results need to be confirmed with the clinical data on the subject device, limited clinical data for a size of the device range) |
|
|
Indicate the specific risks identified in the CER to be monitored |
|
|
Indicate the known undesirable side-effects to be monitored |
|
|
Indicate the known misuse or off label used to be monitored |
|
|
… |
/or
No relevant information from the clinical evaluation report needs to be considered in this PMCF plan.
Relevant information from the risk management file
This PMCF plan for [device short name] is defined based on the outputs of risk management file XXXX rev.Y approved on DD Month YYYY.
The relevant information from the risk management file to be specifically analyzed, followed-up, and evaluated are gathered in the following table.
Table 6: Relevant information from the risk management file
|
Relevant information from the risk management file |
Risk management file section(s) |
|---|---|
|
Indicate the specific risks identified in the risk analysis to be monitored |
|
|
… |
/or
No relevant information from the risk management file needs to be considered in this PMCF plan.
Evaluation of clinical data relating to equivalent or similar devices
PMCF activities of [device short name] also include the collection and evaluation of clinical data on the equivalent and similar devices described in the next table.
The PMCF methods and procedures applied for this evaluation are the same as the general procedures and methods C.1 and C.2 for [device short name]:
- Screening of scientific literature
- Screening of vigilance and recalls in publicly available databases
In addition, clinical data described in the current summary of safety and clinical performance (SSCP) for equivalent/similar devices will be evaluated in the PMCF evaluation report. Applicable to class III and implantable devices only
Table 7: Data on equivalent and similar devices
|
Product Name Manufacturer Name |
Equivalent or similar device |
Intended purpose |
Intended users |
Intended patient population |
Medical condition |
Indication |
Reference to CER |
|
XXXX rev.Y, section Z |
|||||||
Screening of scientific literature for equivalent or similar devices
Objective
- Collect recent information relating to the state of the art
- Collect recent information to confirm the safety and performance acceptance criteria
Description
A literature search will be implemented to detect the published and unpublished articles related to devices similar with or equivalent to [device short name].
The literature search methodology will be carried out in compliance with Section A5 of MEDDEV 2.7/1 rev.4. Research questions will be constructed using a PICO (Populations, Interventions, Comparators, Outcomes) process to justify the selection of relevant keywords.
The literature search will be applied in the following databases:
- Embase
- PubMed
- Cochrane Library
- EU Clinical Trials Register
- Clinicaltrials.gov
- XXXX
In the literature databases, the search queries will be defined using the selected keywords in a way to match with the language of each database used. The queries will have to incorporate the relevant search limitations (e.g., article type, language, as applicable).
The result of literature search will be a list of articles that will be screened in two stages:
- Level-1 screening is based on the titles and abstracts
- Level-2 screening is based on the full articles
The screening process consists of the review of each collected article to confirm if it should be included or excluded based on the inclusion/exclusion criteria.
The literature search will be implemented according to a literature search protocol that is defined based on the literature search protocol from the last CER. The results will be documented in a literature search report.
The result of the literature search will be extracted to ensure the characterization of safety and performance of similar and equivalent devices with the objective to perform a comparison with the safety and performance of [device short name].
The post-market clinical follow-up (PMCF) evaluation report for [device short name] will analyze and summarize the findings resulting from the literature search.
Screening of vigilance and recalls in publicly available database for equivalent or similar devices
Objective
- Collect recent information relating to the state of the art
- Collect recent information to confirm the safety and performance acceptance criteria
Description
A vigilance / recall search will be implemented to detect the clinical risks (i.e., device problem, patient problems) related to devices similar with or equivalent to [device short name].
The vigilance / recall search methodology will be carried out using an approach similar to the literature search methodology. Research questions will be constructed using a PICO process to justify the selection of relevant keyword.
The vigilance / recall search will be applied in the following databases:
- FDA MAUDE
- FDA Medical Device Recalls
- FDA TPLC
- ANSM safety information
- Bfarm Field Corrective Actions
- MHRA Alerts, recalls and safety information: drugs and medical devices
- SwissMedic – FSCA and recall
- DAEN (Database of Adverse Event Notifications) – medical devices
- SARA (System for Australian Recall Actions)
- Canadian recalls and safety alerts
- XXXX
In the vigilance / recall databases, the search queries will be defined using the selected keywords in a way to match with the language of each database used. The queries will have to incorporate the relevant search limitations (e.g., search period).
The result of vigilance / recall searches will be a list of events that will be screened to determine if applicable to devices similar with or equivalent to [device short name].
The vigilance / recall search will be implemented according to a vigilance / recall search protocol that is defined based on the vigilance / recall search protocol from the last CER. The results will be documented in a vigilance / recall search report.
The post-market clinical follow-up (PMCF) evaluation report for [device short name] will analyze and summarize the findings resulting from the vigilance / recall search.
Screening of summary of safety and clinical performance in EUDAMED
Only applicable to class III or implantable devices
Objectives
- Collect recent information to confirm the safety and performance acceptance criteria
Description
For MDR class III and implantable devices, manufacturers are required to make publicly available the summary of safety and clinical performance (SSCP) via EUDAMED. Until EUDAMED becomes fully functional, SSCPs may be found on the websites of manufacturers or in other public locations.
A search will be implemented to find the SSCPs of MDR devices similar or equivalent to [device short name] starting from EUDAMED and manufacturer websites.
The result of the search will be extracted to ensure the characterization of safety and performance of similar and equivalent devices with the objective to perform a comparison with the safety and performance of [device short name].
The post-market clinical follow-up (PMCF) evaluation report for [device short name] will analyze and summarize the findings resulting from the search of SSCPs.
Reference to any applicable common specification(s), harmonized standard(s) or applicable guidance document(s)
|
Reference |
Description |
|---|---|
|
Common specifications |
|
|
Harmonized standards |
|
|
Guidance documents |
|
|
MDCG 2020-7 (April 2020) |
Guidance on PMCF plan template |
|
MDCG 2020-8 (April 2020) |
Guidance on PMCF evaluation report template |
|
XXXX |
|
Estimated date of the PMCF evaluation report
Taking into account the timelines described in the summary table of PMCF activities in Section C, the overall timeline is:
- PMCF data collection period: from XXX to XXX
- PMCF data analysis period: from XXX to XXX
- PMCF evaluation report: XXX
Appendix 1 – List of devices
|
Model number (UDI-DI) |
Device description |
EMDN code |
Lifetime |
Class and rule |
|---|---|---|---|---|
|
Class X / Rule Y |
||||
|
Class X / Rule Y |
||||
|
Class X / Rule Y |
||||
|
Class X / Rule Y |
||||
|
Class X / Rule Y |
||||
|
Class X / Rule Y |
||||
|
Class X / Rule Y |
The complete template content is displayed above. The editable file is available after adding the product to cart.
Related Post-Market Surveillance templates
Strengthen your post-market surveillance documentation with related templates from the same process.
- PMCF Evaluation Report
- Periodic Safety Update Report (PSUR)
- Trend Analysis Tool
- PMS Plan
- PMCF Procedure
Need expert support? Explore Post-Market Surveillance (PMS) & PMCF Services for Medical Devices | Lexqara.
Free